FDA Fast Tracks CTP-543 for Alopecia
FDA Fast Tracks CTP-543 for alopecia areata Concert Pharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation for CTP-543, a novel oral Janus kinase (JAK) inhibitor for the treatment of moderate-to-severe alopecia areata. The FDA grants Fast Track status for Concert Pharmaceuticals’ CTP-543 for the treatment of moderate-to-severe alopecia areata, […]